Navigation Links
Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform

CRANBURY, N.J. and PHILADELPHIA, Aug. 22, 2011 /PRNewswire/ -- Oncobiologics, Inc. and Fox Chase Cancer Center announced today an agreement to co-develop a novel, next-generation bi-specific antibody cancer platform with enhanced therapeutic capabilities against solid tumors. The jointly engineered platform is designed to handle multiple targets, representing a pipeline of promising cancer treatments. This research program is now underway, with preclinical studies expected in Q1-2012 for the first molecule using this platform. Financial terms were not disclosed.

The platform integrates intellectual property originated by both Oncobiologics and Fox Chase. Oncobiologics will play a key role in the discovery program that will be carried out at Fox Chase, and will engage its proof-of-concept engine to develop therapeutic products and move them through clinical trials. The two organizations expect to partner with established pharmaceutical/biopharmaceutical companies for commercialization of drug candidates resulting from the platform, and are actively seeking co-development partners.

"Fox Chase is excited about taking this important step in jointly developing a unique bi-specific antibody platform with Oncobiologics," says Kurt A. Schwinghammer, Ph.D., Vice President of Research and Development Alliances at Fox Chase Cancer Center. "We have been extremely hopeful about the promise of this therapeutic approach."  

Matt Robinson, Ph.D., the principal investigator at Fox Chase and John Cini, Ph.D., Vice President at Oncobiologics, commented, "We believe this platform can improve cancer therapies by improving tumor delivery, enhancing pharmacokinetics, and providing the opportunity for synergistic bi-specific antibody delivery."

"This is an important milestone in demonstrating our mission to increase the flow of biologic drug candidates to the patients who need them," said Pankaj Mohan, Ph.D., Founder & CEO of Oncobiologics. "Strategic partnerships with Fox Chase and other centers of excellence in cancer research are a critical element of our strategy to deliver a holistic approach for treating cancer."  

About Oncobiologics, Inc.

Oncobiologics is a discovery and proof-of-concept engine with the mission of increasing the flow of biologic drug candidates through the industry's development pipeline by eliminating technical and financial barriers. The Oncobiologics team is comprised of senior scientists and technicians from top-tier pharma and biotech organizations with extensive experience developing and commercializing successful biologic drugs. Oncobiologics operates in a state-of-the-art, 25,000-sq.-ft. multi-host facility in central New Jersey. More information can be found at

About Fox Chase Cancer Center

Fox Chase Cancer Center is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX-CHASE or 1-888-369-2427.


Jeremy Caudill

Oncobiologics, Inc.
609-619-3990 ext. 216

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Oncobiologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Henry Schein Announces $200 Million Increase to Stock Repurchase Program
2. ShangPharma Announces Up to $10 Million Share Repurchase Program
3. Masimo Announces Adoption of Stock Repurchase Program
4. Abaxis Announces Stock Repurchase Program
5. Boston Scientific Announces $1.0B Share Repurchase Program
6. Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Authorizes Share Repurchase Program
7. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants
8. BioSpecifics Technologies Corp. Announces Board Authorization of up to $2 Million Share Repurchase Program
9. China Medical Technologies Announces the Purchase of its ADSs by Chengxuan in the Open Market
10. TPI Board Reinstates Stock Repurchase Program
11. Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC
Post Your Comments:
(Date:11/24/2015)... -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") ... and technology platform company serving the pharmaceutical, biotechnology, and ... and the United States ... of shareholders held today, the Company,s shareholders voted in ... previously announced agreement and plan of merger (the "Merger ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 /PRNewswire/ ... leader in non-invasive genetic testing and the ... that it will present at the 27 ... York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, ... Company,s financial results, business activities and financial ...
(Date:11/24/2015)... 2015  In the pharmaceutical industry, companies want to ... quickly uncover new insights, tactics and strategies that will ... --> However, organizations often find it is ... ensure that all rules and regulations are met to ... barrier to efficiently launching market research projects is the ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... of Tri Lite’s personal heating products business. Cozy Products explains what this ... heaters that fit in well with the Cozy Products business model: to sell personal ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android ... The new app features a more intuitive SleepScore™ that rates sleep quality on a ... The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a passenger ... thought there had to be a convenient and comfortable way to protect them from ... disabled individuals to safely travel during cold or inclement weather. In doing so, it ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor of Pulmonary Hypertension ... and groups responsible for advancing care for pulmonary hypertension (PH) patients and helping ... public, will receive special recognition throughout 2016 as part of PHA’s 25th anniversary ...
Breaking Medicine News(10 mins):